Your browser doesn't support javascript.
loading
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Sharma, Abhinav; Pagidipati, Neha J; Califf, Robert M; McGuire, Darren K; Green, Jennifer B; Demets, Dave; George, Jyothis Thomas; Gerstein, Hertzel C; Hobbs, Todd; Holman, Rury R; Lawson, Francesca C; Leiter, Lawrence A; Pfeffer, Marc A; Reusch, Jane; Riesmeyer, Jeffrey S; Roe, Matthew T; Rosenberg, Yves; Temple, Robert; Wiviott, Stephen; McMurray, John; Granger, Christopher.
Afiliação
  • Sharma A; Division of Cardiology, McGill University Health Centre, Montreal, QC, Canada (A.S.).
  • Pagidipati NJ; Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (A.S.).
  • Califf RM; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (N.J.P., J.B.G., M.T.R., C.G.).
  • McGuire DK; Verily Life Sciences and Duke University School of Medicine, Durham, NC (R.M.C.).
  • Green JB; UT Southwestern, Dallas (D.K.M.).
  • Demets D; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (N.J.P., J.B.G., M.T.R., C.G.).
  • George JT; University of Wisconsin, Madison (D.D.).
  • Gerstein HC; Boehringer-Ingelheim International, Ingelheim am Rhein, Germany (J.T.G.).
  • Hobbs T; McMaster University, Hamilton, ON, Canada (H.C.G.).
  • Holman RR; Novo Nordisk, Plainsboro, NJ (T.H.).
  • Lawson FC; Diabetes Trials Unit, University of Oxford, UK (R.R.H.).
  • Leiter LA; Sanofi US, Bridgewater, NJ (F.C.L.).
  • Pfeffer MA; University of Toronto, ON, Canada (L.A.L.).
  • Reusch J; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA (M.A.P.).
  • Riesmeyer JS; University of Colorado School of Medicine, Denver (J.R.).
  • Roe MT; Eli Lilly & Co, Indianapolis, IN (J.S.R.).
  • Rosenberg Y; Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (N.J.P., J.B.G., M.T.R., C.G.).
  • Temple R; National Heart, Lung, and Blood Institute, Bethesda, MD (Y.R.).
  • Wiviott S; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD (R.T.).
  • McMurray J; TIMI Study Group, Harvard Medical School, Boston, MA (S.W.).
  • Granger C; University of Glasgow, Scotland, UK (J.M.).
Circulation ; 141(10): 843-862, 2020 03 10.
Article em En | MEDLINE | ID: mdl-31992065
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Glucose / Hipoglicemiantes Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Glucose / Hipoglicemiantes Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article